CP
VOR icon

Caligan Partners’s Vor Biopharma VOR Stock Holding History

Caligan Partners’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35.4M Hold
1,925,066
– – 1.67% 14
2026
Q1 		$34.3M Buy
1,925,066
+999,999
+108% +$14.1M 2.29% 14
2025
Q4 		$9.96M Buy
+925,067
New +$17.2M 0.82% 19

Other funds holding VOR

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Caligan Partners's VOR Position: Q2 2026 in Review

Caligan Partners held its Vor Biopharma (VOR) position steady in Q2 2026 at 1,925,066 shares worth $35.4M. The position accounts for 1.67% of the portfolio, ranked #14.

Caligan Partners first reported a position in VOR in Q4 2025 and has held it in 3 quarters since. 102 funds tracked by Wall St. Rank hold VOR as of Q2 2026.

  • Caligan Partners held 1,925,066 shares of Vor Biopharma worth $35.4M as of Q2 2026.
  • Caligan Partners left its Vor Biopharma share count unchanged in Q2 2026.
  • Vor Biopharma made up 1.67% of Caligan Partners's portfolio in Q2 2026, its #14 holding.
  • Caligan Partners first reported a position in Vor Biopharma in Q4 2025 and has held it in 3 quarters since.
  • 102 funds tracked by Wall St. Rank held Vor Biopharma as of Q2 2026.

Based on Caligan Partners's 13F filing for Q2 2026, filed 14 Aug 2026.